Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers

Basit Öğe Kaydı
dc.authorid0000-0002-8003-1952
dc.contributor.authorSoysal, Ahmet
dc.contributor.authorGönüllü, Erdem
dc.contributor.authorKarabayır, Nalan
dc.contributor.authorAlan, Servet
dc.contributor.authorAtıcı, Serkan
dc.contributor.authorYıldız, İsmail
dc.contributor.authorEngin, Havva
dc.contributor.authorÇivilibal, Mahmut
dc.contributor.authorKaraböcüoğlu, Metin
dc.date.accessioned2023-03-02T13:16:52Z
dc.date.available2023-03-02T13:16:52Z
dc.date.issued2021
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.description.abstractThe effects of inactivated SARS-CoV-2 vaccine (CoronaVac) on previously naturally infected individuals are unknown. This study compared immunogenicity and reactogenicity of CoronaVac in once naturally infected health-care workers (HCWs) and uninfected HCWs. All HCWs were immunized with two doses of CoronaVac (600 U/0.5 ml) intramuscularly at a 28-day interval. Adverse reactions were obtained by web-based questionnaires or telephone calls seven days after each vaccine dose. Detection of antibody levels against the receptor-binding domain (RBD) of SARS-CoV-2 spike protein was done four weeks after the second dose of the vaccine. We enrolled 103 previously naturally infected and 627 uninfected HCWs. The mean time for vaccination after the first nasopharyngeal SARS-CoV-2 positivity was 64 days (range: 15-136 days) in previously naturally infected HCWs. Among the previously naturally infected HCWs, 41 (40%) were asymptomatic, 52 (50%) had mild upper respiratory tract infections, 10 (105) had pneumonia, and only 6 (5%) were hospitalized. Any reported adverse reactions, either from the first dose or the second dose of vaccine administration, did not differ between previously infected and uninfected HCWs. Anti-RBD antibody titers were obtained in 50 (51%) of 103 previously infected HCWs and 142 (23%) of 627 uninfected HCWs. Anti-RBD antibody titers were significantly higher in HCWs with a previous natural infection (median 1220 AU/ml, range: 202-10328 AU/mL) than in uninfected HCWs (median: 913 AU/ml, range: 2.8-15547 AU/mL, p = .032). CoronaVac administration was safe and may elicit higher antibody responses in previously naturally infected individuals.
dc.identifier.citationSoysal, A., Gönüllü, E., Karabayır, N., Alan, S., Atıcı, S. ve Yıldız, İ. (2021). Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers. Human Vaccines and Immunotherapeutics, 17(11), 3876-3880. https://dx.doi.org/10.1080/21645515.2021.1953344
dc.identifier.doi10.1080/21645515.2021.1953344
dc.identifier.endpage3880
dc.identifier.issn2164-5515
dc.identifier.issn2164-554X
dc.identifier.issue11
dc.identifier.pmid34324409
dc.identifier.scopus2-s2.0-85111796073
dc.identifier.scopusqualityQ1
dc.identifier.startpage3876
dc.identifier.urihttps://dx.doi.org/10.1080/21645515.2021.1953344
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10560
dc.identifier.volume17
dc.identifier.wos000679215500001en_US
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKarabayır, Nalan
dc.language.isoen
dc.publisherTaylor and Francis Ltd.
dc.relation.ispartofHuman Vaccines and Immunotherapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectSARS-coV-2 Inactivated Virus Vaccine
dc.subjectCoronaVac
dc.subjectHealth Care Workers
dc.subjectVaccine Antibody Response
dc.subjectVaccine Adverse Effects
dc.subjectTurkey
dc.titleComparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Karabayir-Nalan-2021.pdf
Boyut:
667.97 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu